Shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) saw strong trading volume on Thursday . 997,169 shares changed hands during mid-day trading, an increase of 549% from the previous session’s volume of 153,758 shares.The stock last traded at $14.00 and had previously closed at $12.92.

Several research analysts have commented on the company. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $38.00 price target on shares of Aimmune Therapeutics in a research report on Tuesday, May 17th. Bank of America Corp. reaffirmed a “buy” rating on shares of Aimmune Therapeutics in a research report on Monday, May 16th. Wedbush reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a research report on Wednesday, August 10th. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $35.00 price target on shares of Aimmune Therapeutics in a research report on Friday. Finally, Zacks Investment Research downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 15th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $33.40.

The stock’s 50 day moving average price is $11.90 and its 200-day moving average price is $13.80. The stock’s market cap is $608.46 million.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.01. On average, equities analysts predict that Aimmune Therapeutics Inc. will post ($1.71) EPS for the current year.

In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the company’s stock in a transaction dated Tuesday, May 31st. The stock was sold at an average price of $15.23, for a total transaction of $3,655,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

An institutional investor recently raised its position in Aimmune Therapeutics stock. RS Investment Management Co. LLC increased its stake in shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) by 12.3% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 804,143 shares of the company’s stock after buying an additional 88,180 shares during the period. RS Investment Management Co. LLC owned approximately 1.90% of Aimmune Therapeutics worth $14,836,000 at the end of the most recent reporting period.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.